Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany
Authors:
Open Access
- 23 November 2020
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 77 (5) , 767-775
Abstract
Purpose: Most psychiatric drugs, such as antidepressants (AD) and antipsychotics (AP), may cause cardiac adverse events (CAE). We used summaries of product characteristics (SmPC) for assessing the likelihood of AD and AP to cause CAE.Methods: We identified all original medicinal products (OMP) of AD and AP approved in Germany. We searched for their SmPCs using the online services of PharmaNet.Bund, Gelbe liste®, Rote Liste®, Fachinfo-Service®, and via manufacturer contact. We extracted frequencies of reported CAE (QT prolongation, Torsade de Pointes tachycardia, and ventricular arrhythmia) and performed a risk assessment.Results: We obtained the SmPCs of 24 AD and 26 AP identified as OMP. Comparably high reported frequencies regarding QT prolongation were found for Invega® (paliperidone), Serdolect® (sertindole) (≥ 1/100 and < 1/10), and Zoloft® (sertraline) (≥ 1/10.000 and < 1/1000); regarding Torsade de Pointes tachycardia were found for Serdolect® (≥ 1/1000 to < 1/100), Zoloft®, and Trevilor® (venlafaxine) (≥ 1/10.000 and < 1/1000); regarding ventricular tachycardia for Solian® (amisulpride), Xomolix® (droperidol), Zyprexa® (olanzapine), and Trevilor® (≥ 1/10.000 and < 1/1000).Conclusion: The risk and frequency of CAE, as reported in the SmPCs, varied significantly among substances and between groups. There are more reports for AP than AD. The AP with the most frequently reported CAE (QT prolongation and Torsade de Pointes tachycardia) was Serdolect®; for AD, Zoloft® (QT prolongation, Torsade de Pointes tachycardia) and Trevilor® (Torsade de Pointes tachycardia and ventricular tachycardia) carried a higher cardiac risk.Keywords
Funding Information
- Universitätsklinikum Ulm
This publication has 17 references indexed in Scilit:
- Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort studyBMJ Open, 2020
- A comparative study of QT prolongation with serotonin reuptake inhibitorsPsychopharmacology, 2017
- Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults ‐ a Swedish nationwide studyBritish Journal of Clinical Pharmacology, 2016
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- QTc Prolongation by Psychotropic Drugs and the Risk of Torsade de PointesDeutsches Ärzteblatt international, 2011
- Psychotropic medications and the risk of sudden cardiac death during an acute coronary eventEuropean Heart Journal, 2011
- The European Post-marketing Observational Sertindole Study: an investigation of the safety of antipsychotic drug treatmentEuropean Archives of Psychiatry and Clinical Neuroscience, 2009
- Infovigilance: Reporting Errors in Official Drug Information SourcesPharmacy World & Science, 2005
- Psychotropic Drugs, Cardiac Arrhythmia, and Sudden DeathJournal of Clinical Psychopharmacology, 2003
- Conduction Disturbances Associated with Administration of Butyrophenone Antipsychotics in the Critically Ill: A Review of the LiteraturePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997